US OptionsDetailed Quotes

NBIX250516C130000

Watchlist

2.70
0.000.00%

15min DelayClose Apr 24 16:00 ET

0.00High0.00Low

Neurocrine Biosciences Stock Discussion

Teddy123

Mar 31 20:35

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

$Neurocrine Biosciences (NBIX.US)$
New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate

Teddy123

Mar 20 20:44

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

$Neurocrine Biosciences (NBIX.US)$
Breakthrough: INGREZZA Achieves 59% Remission in Tardive Dyskinesia Patients Over 48 Weeks

Teddy123

Mar 17 20:38

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

$Neurocrine Biosciences (NBIX.US)$
Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions

Teddy123

Mar 5 21:51

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

$Neurocrine Biosciences (NBIX.US)$
Can Neurocrine's New VMAT2 Inhibitor Replicate Its Previous FDA Success? Phase 1 Trial Launches

Kevin Travers

Feb 8 05:05

Columns Wall Street Today: One More Earnings Week Down

Overall, the market traded lower Friday, after a week of trade and earnings upsets.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded down 0.95%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.99%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 1.36%.
MACRO
Macroeconomic news might have swayed the market as jobs and unemployment data came in. The economy added 143,000 jobs in January, according to the BLS, which was low, but N...

Live Stock Financial Podcast. What are you watching on the market?

Meltyy

Dec 17, 2024 15:56

📌 1 PDUFA this weekand 6 more upcoming this month! 🚀

🔔 This Week’s PDUFA:
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...